Table 1 Results of IHC showing tissue expressions of CTSF, FBLN1, and AKR1B10 in each clinical group in cohort 3.

From: Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer

Occur/total (%)

 

Brain metastasis

Glioma

P

Schwannoma

P

NSCLC without BM

P

Corresponding non-tumour

P

CTSF

         

 Strong positive

2/47 (4%)

0/9 (0%)

0.013*

0/5 (0%)

0.006**

0/15 (0%)

0.017*

0/13 (0%)

0.005**

 Positive

21/47 (45%)

2/9 (22%)

0/5 (0%)

2/15 (13%)

0/13 (0%)

 Weak Positive

13/47 (28%)

0/9 (0%)

0/5 (0%)

3/15 (20%)

4/13 (31%)

 Negative

11/47 (23%)

7/9 (78%)

5/5 (100%)

10/15 (67%)

9/13 (69%)

FBLN1

         

 Strong positive

0/47 (0%)

0/9 (0%)

0.001**

0/5 (0%)

0.003**

0/15 (0%)

0.031*

0/13 (0%)

0.224

 Positive

5/47 (11%)

0/9 (0%)

0/5 (0%)

2/15 (13%)

0/13 (0%)

 Weak Positive

30/47 (64%)

1/9 (11%)

0/5 (0%)

4/15 (27%)

7/13 (54%)

 Negative

12/47 (26%)

8/9 (89%)

5/5 (100%)

9/15 (60%)

6/13 (46%)

AKR1B10

         

 Strong positive

5/47 (11%)

0/9 (0%)

0.385

0/5 (0%)

0.016*

0/15 (0%)

0.323

0/13 (0%)

0.000***

 Positive

19/47 (40%)

2/9 (22%)

0/5 (0%)

5/15 (33%)

0/13 (0%)

 Weak Positive

21/47 (45%)

6/9 (67%)

3/5 (60%)

10/15 (67%)

0/13 (0%)

 Negative

2/47 (4%)

1/9 (11%)

2/5 (40%)

0/15 (0%)

13/13 (100%)

  1. Results of immunohistochemistry (IHC) showing tissue expressions of Cathepsin F (CTSF), Fibulin-1 (FBLN1) and Aldo-keto reductase family 1 member B10 (AKR1B10) in each clinical group in cohort 3. Statistical analyses of IHC staining expression between non-small cell lung cancer (NSCLC) brain metastasis (BM) and each control are shown. Corresponding non-tumour is matched with 13 of 15 NSCLC without BM.
  2. *P < 0.05.
  3. **P < 0.01.
  4. ***P < 0.001.
Back to article page